The U.S. Food and Drug Administration Approves Zanubrutinib (Brukinsa, BeiGene USA, Inc.) with Obinutuzumab for Relapsed/Refractory Follicular Lymphoma (FL)
On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved…
On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved…
Celebrating the Original ‘Chemo Diva’ Upon receiving a lymphoma diagnosis, it’s not uncommon to search…
Where Are They Now? Ryan Lynch, MD Dr. Ryan Lynch is a hematologist-oncologist at Fred…
Advancing Cures and Developing the Next Generation of Lymphoma Researchers Growing up in Spoleto, Italy,…
Morton Coleman, MD Innovation Fund Dr. Morton Coleman is a world-renowned and highly respected medical…
Dear Friends of LRF, The Lymphoma Research Foundation (LRF) is defined by its tirelesscommitment to…
Updates from the 2023 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF)…
ASH 2023: Increased Metabolism in High IRF4-Expressing Lymphoma Cells Limits the Availability of Glucose in…
ASH 2023: Durable Responses Observed with Valemetostat Improved Outcomes in Second-Line Treatment of Large B-Cell…
ASH 2023: Durable Responses Observed with Valemetostat Tosylate Treatment in Relapsed/Refractory Peripheral T-Cell Lymphoma Treatment…